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Abstract
Aims: To identify factors associated with entering any methadone treatment at first admission at an NHS treatment centre in Italy and to
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Pnvestigate determinants of receiving detoxification or maintenance methadone treatments.
ethods: Data were analysed from 565 heroin addicts who entered for the first time one of 90 NHS treatment centres in 12 Italian regions
etween September 1998 and March 2001. Subjects were interviewed at admission by the centre’s staff and followed-up for 18 months.
etails on treatments provided were recorded using a standardised form. Random effects logistic regression analysis was applied.
esults: Factors positively associated with any methadone treatment assignment were: being younger than 25 years and using heroin more
han twice a day, having been recently incarcerated, and living with a partner. Independent predictors of admission to methadone maintenance
ere injecting heroin, having sex without a condom in the previous six months, being HIV positive and having been enrolled at a NHS TC
here a psychiatrist was present. Using heroin once a day or more and using cocaine were factors associated with enrolment into detoxification
reatment. A significant heterogeneity between centres was observed.
onclusions: Results from this study give an insight into different patient profiles who are enrolled in methadone treatments. The observed
eterogeneity between centres indicates the need to develop and implement common guidelines for the access of heroin addicts to substitution
reatment.
2005 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Heroin addiction is associated with considerable social
and medical consequences and represents a serious health
problem in the young adult population. Drug treatment isarobene, F. Cipriani, L. Cuomo, R. Diecidue, S. Della Bona, F. Faggiano,
. Grande, R. Lovaste, N. Magliocchetti, C. Martini, F. Mathis, L. Montina,
.P. Pani, R.M. Pavarin, G. Piras, R. Sbrana, P. Schifano, G. Salamina, A.
widely recognized as an important component of the pub-
lic health effort to reduce drug use and drug injection andScarmozzino, S. Scondotto, P. Sgarzini, C. Sorio, M. Triassi, E. Versino, G.
Villani; Regional coordinators: F. Baraldi, G. Cabras, S. Canfarotta, I. Carta,
L. Castegnaro, M. De Florio, M. Di Giorni, M. Ferri, S. Fratini, F. Fratta, S.
Geninatti, S. Giglio, A. Iannaccone, F. Lampis, M. Maisto, P.P. Manassero,
G. Marra, A. Peris, M.T. Revello, R. Schiaffino, N. Scola, G. Seddone, A.
Testa; Ethical committee: P. Jarre, E. Bignamini, P.M. Furlan, M.B. Ghisleni,
L. Grosso, V. Mitola, M.T. Ninni, M.R. Ranieri, M. Ruschena, P. Vineis.
to control the spread of HIV among injecting drug addicts
(McCusker et al., 1996; Booth et al., 1996; Hubbard et al.,
1988; Metzger et al., 1998; Sisk et al., 1990). Independent of
treatment typology, substance abuse treatment has also been
found to be effective in improving family relations, physical
and psychological health and in reducing criminal activity
0376-8716/$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.
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(McLellan et al., 1986; Strain et al., 1991). Many studies have
been carried out, mainly after the onset of the HIV epidemic
(Mattick et al., 2002; Zule and Desmond, 2000; John et al.,
2001; Schu¨tz et al., 1994; Shah et al., 2000), to investigate fac-
tors encouraging entry into drug abuse treatment programs,
in particular methadone maintenance, to reduce the public
health burden of substance abuse. A variety of treatments
are available for heroin addiction with a variety of goals,
clinical practises and effectiveness. While there is sound
evidence of efficacy based on randomised controlled trials
and systematic reviews (Caplehorn et al., 1993; Gearing and
Schweitzer, 1974; Amato et al., 2002a) for methadone main-
tenance treatment (MMT), for other treatments the evidence
is far from satisfactory (Amato et al., 2002b). Methadone
maintenance has been consistently associated with cessation
of drug use and lower rate of injection, needle exchange and
HIV infection (Mattick et al., 2002; Metzger et al., 1993;
Gossop et al., 2003). Enrolment into methadone mainte-
nance is related with a long history of use, prior treatment
episodes and living with a partner while entry into methadone
detoxification treatments seems closely associated with
recent drug use and recent complications of injecting
drugs.
Since the 1980s treatment of drug addiction in Italy has
been provided mainly on an outpatient basis, within the
National Health Service, through a network of treatment
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2. Methods
2.1. Context
This study was part of the VEdeTTE study described in
detail elsewhere (Bargagli et al., in press). Briefly, 10,454
heroin addicts were enrolled between September 1998 and
March 2001 who were: 18 years of age or over, entering
treatment at one of 115 NHS treatment centres in 13 Ital-
ian regions. At enrolment subjects were defined as “incident
cases” (N= 1249; 12.0%) if they were starting treatment for
the first time at a specific TC during the study period; “re-
entry cases” (N= 1981; 18.9%) if they were not in treatment
at the beginning of the study but had been treated by the cen-
tre in the past, and “prevalent cases” (N= 7224; 69.1%) if
they were already in treatment at the beginning of the study.
To enrol patients, a formal written consent was requested.
After the consent, a standardised intake questionnaire was
administered by a trained interviewer, usually belonging to
the centre’s staff. There was a delay between the start of
treatment and the administration of the intake questionnaire.
Among incident and re-entry cases, the median delay was 19
days, but 42.4% of these patients were interviewed 30 days
after the start of treatment.
2.2. Study population
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oentres and agencies run by non-governmental organiza-
ions (NGOs). NHS treatment centres offer a broad spec-
rum of treatment modalities. The 554 treatment centres
resent in Italy at the time of this study offered the same
ypes of treatments: methadone maintenance (occasionally
uprenorphine); detoxification with substitution drugs, es-
ecially methadone, naltrexone, therapies with symptomatic
nd/or antagonist drugs, and various types of psychosocial
nterventions. The provision of these treatments vary widely
rom region to region and, even from treatment centre to treat-
ent centre. In 2001, the percentage of clients who entered
ong term methadone treatment (>6 months) ranged from
0% in Liguria (Ministry of Health, 2002) to 50% in the
azio region. In the same year, the availability of MMT dif-
ered within the Lazio region, ranging from 3.6 to 68.0%
Pasqualini et al., 2002). Moreover, although methadone
aintenance at high dosage (ranging from 60 to 100 mg/day)
s recommended for reducing illicit opioid use and promot-
ng longer retention in treatment (Faggiano et al., 2003),
osages provided tend to be low and vary greatly between
entres.
Therefore, in spite of the overwhelming evidence of
fficacy for methadone maintenance treatment, the or-
anisation and regulation of this treatment in Italy vary
reatly.
The aims of the present analysis were to identify factors
ssociated with entering any methadone treatment at first
dmission at an NHS treatment centre and factors associ-
ted with receiving detoxification or maintenance methadone
reatments.In order to analyse determinants of the first treatment as-
igned, we included only first time patients to the treatment
entre. It does mean that we included patients who could have
een previously treated in other treatment centres, but enter-
ng for the first time the enrolment centre (incident cases,
= 1249). As a consequence we excluded all the re-entry
ases (N= 1981) and the prevalent ones (N= 7224). Further-
ore, we excluded the incident cases for whom information
as collected more than 30 days after admission (N= 684;
4.7% of 1249); for these patients information on heroin use
efore entering treatment have not been considered valid for
he present analysis.
According to the previous criteria, the study population
ncluded 565 “incident cases” who entered 90 of 115 centres
articipating in the VedeTTE study. The rules for treatment
dmittance in Italy require that a patient can be admitted only
o the centre of his/her own area of residence; therefore, peo-
le who moved might have already had contact with another
reatment centre. For these people information on possible
revious treatments was available, and considered as a co-
ariate. Information on typology of previous treatments was
ot known.
.3. Data collection
Data collection was performed using research in-
truments especially designed for the VEdeTTE study:
he Intake Questionnaire, administered at the moment
f treatment admission, and the Treatment Registra-
A.M. Bargagli et al. / Drug and Alcohol Dependence 79 (2005) 191–199 193
tion Form, used to gather detailed information on treat-
ments.
Heroin addicts who agreed to participate in the study were
interviewed by a member of the centre’s staff at admission.
Participants provided socio-demographic information, his-
tory of previous treatments, age of first use of heroin, pattern
of drug use in the previous 30 days (i.e. route of heroin ad-
ministration and frequency of heroin use and cocaine use),
sexual and injecting practises during the previous six months
and lifetime overdose episodes. Socio-demographic variables
included gender, age, civil status, living situation, educa-
tional level, employment status, legal problems, and his-
tory of imprisonment. Data on HIV, HBV and HCV sero-
logical status and psychiatric diagnoses other than drug de-
pendence were retrieved from clinical records. We also in-
cluded in the analysis if a psychiatrist was present or not at
admission.
Information on the first treatment was gathered from the
Treatment Registration Form, which recorded for each treat-
ment the beginning and ending date, dosages and frequency
of administration of drugs, timetable and duration of psycho-
social sessions and outcome. In the Treatment Registration
Form, methadone maintenance was defined as “methadone
therapy at stable doses and varying not more than 20 mg”.
Methadone detoxification was defined as “methadone ther-
apy at decreasing doses, lasting less than 180 days and aimed
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Potential two-way statistical interactions were assessed
between all variables, independently predictive of the out-
come in the final models.
Missing observations were excluded from the multivari-
ate analysis. Statistical analyses were performed using SAS
version 8.2 and STATA version 8.0 for Windows.
3. Results
Of the 565 heroin addicts who were included in the study,
373 (66.0%) entered methadone treatment as first treatment
at admission; of these, 143 (38.3%) were enrolled in main-
tenance treatments and 230 (61.7%) in detoxification treat-
ments. Psychosocial interventions were associated in about
47% of the 373 methadone treatments. Among heroin addicts
that did not enter methadone treatments (N= 192), 70% were
offered only psychotherapy, psychological support, or coun-
selling while the remaining (30%) received pharmacological
therapies with antagonists, symptomatic drugs, or naltrexone.
Tables 1 and 2 describe the socio-demographic and drug use
characteristics of heroin users according to participation in
methadone treatment (both maintenance and detoxification)
and in other treatments. In the total sample of heroin users
included in this study, the mean age was 28 years, 85% were
males, 60% lived alone or with friends, 42% were steadily
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to reach a drug free status”.
.4. Statistical analyses
Participants were grouped according to the two main
ypes of first treatment: methadone detoxification or mainte-
ance (first group), and all other pharmacological treatments
nd psychosocial programs (second group). If methadone
as used in conjunction with another pharmacological treat-
ent or psychosocial program, clients were assigned to
he methadone group. Heroin users entering any methadone
reatment were compared to those starting other treatment
ypologies, to identify conditions that might influence as-
ignment to substitution therapies. Subsequently, heroin
sers entering methadone maintenance have been com-
ared to those starting a detoxification treatment, in order
o investigate criteria on admission to different substitution
pproaches.
Logistic regression models were applied for both compar-
sons. We introduced a random effect in the models to take
nto account the potential correlation existing among indi-
iduals enrolled at the same treatment centre, and to obtain
nbiased estimates. Covariates to be entered into logistic re-
ression models were selected through a backward stepwise
rocedure, with p< 15 for the likelihood ratio as the entry
riterion and p> 2 set as the criterion for removal from the
odel. Among HIV, HBV, and HCV we only included in the
odels the first one, because they were highly correlated.
esults are reported only for variables entered in the final
odel.mployed and 10% reported having been incarcerated within
he past 12 months. The mean age at first heroin use was 20
ears (S.D. 4.7), the mean length of heroin use was 7.6 years
S.D. 6.1), 67% of people enrolled injected heroin and more
han 80% used at least daily. Among those using less than
aily, 50% use at least seven times per month.
HIV prevalence among recruited heroin addicts was 2%,
et for many patients (56%) the result of the HIV test was not
vailable when treatment began. Most heroin addicts (89.7%)
eported at least one episode of lifetime overdose. Four per-
ent of clients had a psychiatric diagnosis other than drug
ddiction without differences among treatment groups. For a
igh proportion of subjects this information was not available
29.2%).
More subjects who began any methadone treatment were
iving with a partner, had been incarcerated within 12 months
efore the admission and reported a high frequency of use in
he past 30 days (Table 1) than heroin users entering other
reatments.
More clients entering MMT injected heroin and reported a
ower frequency of use than those who started detoxification
reatment (Table 2). Tables 3 and 4 show the results of the two
ultiple logistic regression models identifying correlates of
nrolment in any methadone treatment and methadone main-
enance. Living with a partner and having been incarcerated
roved to be independent predictors for entry into methadone
reatments (ORs 3.25, 95% CI: 1.71–6.21 and 3.32, 95% CI:
.30–8.47, respectively). A statistically significant interac-
ion was observed between age at enrolment in methadone
reatment and frequency of heroin use. For heroin addicts
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Table 1
Characteristics of heroin addicts entering treatment
Any methadone program (N= 373) Other treatments (N= 192) Total (N= 565) p-value**
N Percentagea N Percentagea N Percentagea
Gender
Males 314 84.2 168 87.5 482 85.3
Females 59 15.8 24 12.5 83 14.7 0.29
Age at admission
<25 years 131 35.1 69 35.9 200 35.4
25–29 years 92 24.7 62 32.3 154 27.3 0.08
≥30 years 150 40.2 61 31.8 211 37.3
Civil status
Single/divorced 273 73.2 155 80.7 428 75.8
Married/steady relationship 100 26.8 37 19.3 137 24.2 0.05
Living situation
Alone/with friends 205 55.6 132 68.8 337 60.1
Parents/relatives 41 11.1 18 9.4 59 10.5
Partner 116 31.4 35 18.2 151 26.9 0.00
Residential treatment centres 1 0.3 5 2.6 6 1.1
Homeless 6 1.6 2 1.0 8 1.4
Educational level
≤5 years 58 15.5 30 15.7 88 15.6
6–8 years 207 55.5 106 55.5 313 55.5 0.99
>8 years 108 29.0 55 28.8 163 28.9
Employment status
Unemployed 116 31.6 68 35.6 184 33.0
Occasionally employed 100 27.2 41 21.5 141 25.3 0.31
Steadily employed 151 41.1 82 42.9 233 41.8
History of imprisonmentb
No 326 87.4 181 94.3 507 89.7 0.01
Yes 47 12.6 11 5.7 58 10.3
Age at first use of heroin
≤16 74 19.9 24 12.6 98 17.4
>16 298 80.1 167 87.4 465 82.6 0.03
Route of administration
Other 124 33.5 60 31.4 184 32.8
Injected 246 66.5 131 68.6 377 67.2 0.62
Frequency of use
<1/day 63 16.9 42 21.9 105 18.6
1–2/day 155 41.6 91 47.4 246 43.5 0.04
>2/day 155 41.6 59 30.7 214 37.9
Lifetime overdose
No 39 10.6 18 9.6 57 10.3 0.73
Yes 330 89.4 169 90.4 499 89.7
Use of cocaine
No 246 66.3 129 67.9 375 66.8
Yes 125 33.7 61 32.1 186 33.2 0.70
History of lifetime treatment
No 200 53.6 118 61.5 318 56.3
Yes 173 46.4 74 38.5 247 43.7 0.07
Sex without a condomc
No 318 86.9 166 90.7 484 88.2
Yes 48 13.1 17 9.3 65 11.8 0.19
HIV test
Negative 142 38.1 95 49.5 237 41.9
Positive 10 2.7 2 1.0 12 2.1 0.02
Not available 221 59.2 95 49.5 316 55.9
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Table 1 (Continued )
Any methadone program (N= 373) Other treatments (N= 192) Total (N= 565) p-value**
N Percentagea N Percentagea N Percentagea
Other psychiatric diagnoses
No 236 63.3 139 72.4 375 66.5
Yes 16 4.3 9 4.7 25 4.4 0.06
Not available 121 32.4 44 22.9 165 29.2
Psychiatrist at centre
No 167 44.8 66 34.6 233 41.3
Yes 206 55.2 125 65.4 331 58.7 0.02
Methadone program vs. other types of treatment.
a Valid percent.
b In the previous 12 months.
c In the previous 6 months.
∗∗ χ2-test.
Table 2
Characteristics of heroin addicts entering treatment
Methadone maintenance (N= 143) Methadone detoxification (N= 230) Total methadone (N= 373) p-value**
N Percentagea N Percentagea N Percentagea
Gender
Males 125 87.4 189 82.2 314 84.2
Females 18 12.6 41 17.8 59 15.8 0.18
Age at admission
<25 years 47 32.9 84 36.5 131 35.1
25–29 years 29 20.3 63 27.4 92 24.7 0.09
≥30 years 67 46.9 83 36.1 150 40.2
Civil status
Single/divorced 102 71.3 171 74.3 273 73.2
Married/steady relationship 41 28.7 59 25.7 100 26.8 0.52
Living status
Alone/with friends 82 57.7 123 54.2 205 55.6
Parents/relatives 16 11.3 25 11.0 41 11.1
Partner 42 29.6 74 32.6 116 31.4 0.89
Residential treatment centres 0 0.0 1 0.4 1 0.3
Homeless 2 1.4 4 1.8 6 1.6
Educational level
≤5 years 24 16.8 34 14.8 58 15.5
6–8 years 85 59.4 122 53.0 207 55.5 0.22
>8 years 34 23.8 74 32.2 108 29.0
Employment status
Unemployed 47 33.3 69 30.5 116 31.6
Occasionally employed 37 26.2 63 27.9 100 27.2 0.85
Steadily employed 57 40.4 94 41.6 151 41.1
History of imprisonmentb
No 130 90.9 196 85.2 326 87.4
Yes 13 9.1 34 14.8 47 12.6 0.11
Age at first use of heroin
≤16 24 16.8 50 21.8 74 19.9
>16 119 83.2 179 78.2 298 80.1 0.23
Route of administration
Other 37 26.2 87 38.0 124 33.5
Injected 104 73.8 142 62.0 246 66.5 0.02
Frequency of use
<1/day 37 25.9 26 11.3 63 16.9
1–2/day 57 39.9 98 42.6 155 41.6 0.00
>2/day 49 34.3 106 46.1 155 41.6
196 A.M. Bargagli et al. / Drug and Alcohol Dependence 79 (2005) 191–199
Table 2 (Continued )
Methadone maintenance (N= 143) Methadone detoxification (N= 230) Total methadone (N= 373) p-value**
N Percentagea N Percentagea N Percentagea
Lifetime overdose
No 13 9.2 26 11.4 39 10.6
Yes 128 90.8 202 88.6 330 89.4 0.51
Use of cocaine
No 106 74.6 140 61.1 246 66.3
Yes 36 25.4 89 38.9 125 33.7 0.00
History of lifetime treatment
No 76 53.1 124 53.9 200 53.6
Yes 67 46.9 106 46.1 173 46.4 0.88
Sex without a condomc
No 115 82.1 203 89.8 318 86.9
Yes 25 17.9 23 10.2 48 13.1 0.03
HIV test
Negative 61 42.7 81 35.2 142 38.1
Positive 7 4.9 3 1.3 10 2.7 0.03
Not available 75 52.4 146 63.5 221 59.2
Other psychiatric diagnoses
No 91 63.6 145 63.0 236 63.3
Yes 7 4.9 9 3.9 16 4.3 0.22
Not available 45 31.5 76 33.0 121 32.4
Psychiatrist at centre
No 49 34.3 118 51.3 167 44.8
Yes 94 65.7 112 48.7 206 55.2 0.00
Methadone maintenance programs versus methadone detoxification.
a Valid percent.
b In the previous 12 months.
c In the previous 6 months.
∗∗ χ2-test.
younger than 25 years the adjusted OR of entering methadone
treatments was 2.57 (95% CI: 0.83–8.01) for once or twice
a day users and 5.93 (95% CI: 1.78–19.77) for more than
twice a day users. No statistically significant associations
were found in older age groups for any frequency of use.
However, while in the 25–29 age group we did not find any
specific trend in the odds ratio estimates, in the oldest age
group (≥30years) a decreasing trend for frequency of use
was observed, exactly opposite the younger than 25 group.
In the multivariate model, injectors were more likely to par-
ticipate in methadone maintenance than non injecting users
(OR 2.55, 95% CI: 1.12–5.76). Having sex without a condom
in the prior six months and being HIV positive were also inde-
pendently associated with entry into MMT (ORs 2.92, 95%
CI: 1.07–7.93 and 15.22, 95% CI: 1.04–223.31, respectively)
while decreased odds of participation in methadone mainte-
nance were observed for heroin addicts who used cocaine
(OR 0.32, 95% CI: 0.14–0.72) and used heroin once a day
or more (OR 0.22, 95% CI: 0.10–0.63 and 0.32, 95% CI:
0.11–0.90). The adjusted odds ratio of entering methadone
maintenance was 9.00 (95% CI: 2.78–29.11) for heroin ad-
dicts enrolled in a treatment centre with a psychiatrist on staff.
No statistically significant interactions were found among
variables included in the multivariate analysis.
In the logistic models for enrolment in any methadone
treatment and methadone maintenance, high intra-class cor-
relation coefficients were observed (0.71, 95% CI: 0.57–0.83;
and 0.85, 95% CI: 0.72–0.92, respectively).
4. Discussion
This study identified some of the factors associated with
enrolment into any methadone treatment and into methadone
maintenance treatment in a sample of heroin addicts recruited
at their first admission to treatment centres in Italy.
Factors predicting enrolment into any methadone treat-
ment, versus other pharmacological or psychosocial treat-
ments, seem to distinguish two different populations of heroin
addicts: very young patients reporting high-risk addiction and
social behaviours (recent arrest and using heroin more than
twice a day), and an older, more stable group (living with a
partner). The subsequent analysis showed that, as expected,
heroin addicts with poorer health conditions and high-risk
behaviours, such as injecting heroin, having sex without a
condom in the previous 6 months, and being HIV positive,
are more likely to be assigned to methadone maintenance.
This should be taken into account when effectiveness of
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Table 3
Factors associated with enrolment in any methadone program: final random
effects logistic regression model
Variablea OR 95% CI
Age at admission * frequency of use
<25
<1/day 1
1–2/day 2.57 0.83–8.01
>2/day 5.93 1.78–19.77
25–29
<1/day 0.90 0.22–3.65
1–2/day 1.00 0.31–3.22
>2/day 1.72 0.49–6.07
≥30
<1/day 3.77 0.97–14.6
1–2/day 2.39 0.71–7.99
>2/day 1.70 0.51–5.65
Living situation
Alone/with friends 1
Parents/relatives 1.81 0.79–4.19
Partner 3.25 1.71–6.21
Residential TCs 0.13 0.01–1.98
Homeless 1.56 0.21–11.5
History of imprisonmentb
No 1
Yes 3.32 1.30–8.47
ρ* 0.71 0.57–0.83
a Other variables included in the model: gender, employment status, age
at first heroin use, HIV test, history of treatment, presence of a psychiatrist
at centre.
b In the previous 12 months.
∗ Likelihood ratio test of ρ = 0; p< 0.001.
methadone maintenance treatment is evaluated in observa-
tional studies.
A high frequency of heroin use, and cocaine use are related
to a higher probability of receiving detoxification treatment.
This finding was quite surprising, but could be the result of the
therapeutic alliance between doctors and poorly motivated
patients who ask for methadone detoxification in order to
continue injecting heroin.
We also found that patients entering a treatment cen-
tre with a psychiatrist on staff are more likely to receive
methadone maintenance. No previous studies have investi-
gated the role of treatment centre staff make up. In Italy
any type of physician in public treatment centres, can pre-
scribe methadone, but we believe that the presence of a psy-
chiatrist may better support long-term substitution therapy.
Most guidelines stress the importance of co-operation be-
tween methadone-prescribing doctors and psycho-therapists
in order to establish a good relationship with the patient and to
enhance retention in treatment. Furthermore, the presence of
a psychiatrist in a treatment centre could be a proxy of other
centre characteristics, such as more structured and organised
services, which provides the support necessary to manage a
maintenance approach. In a separate analysis we used the
available information on centre characteristics to define a
centre profile indicator, which proved to be not associated
with treatment choice. However, the information available
Table 4
Factors associated with enrolment in methadone maintenance treatment:
final random effects logistic regression model
Variablea OR 95% CI
Route of administration
Other 1
Injected 2.55 1.12–5.76
Frequency of use
<1/day 1
1–2/day 0.22 0.10–0.63
>2/day 0.32 0.11–0.90
Use of cocaine
No 1
Yes 0.32 0.14–0.72
Sex without a condomb
No 1
Yes 2.92 1.07–7.93
HIV test
Negative 1
Positive 15.22 1.04–223.31
Not available 0.94 0.43–2.03
Psychiatrist at centre
No 1
Yes 9.00 2.78–29.11
ρ* 0.85 0.72–0.92
a Other variables included in the model: gender, age at admission, living
status, age at first heroin use, history of prior arrest, history of treatment.
b In the previous 6 months.
∗ Likelihood ratio test of ρ = 0; p< 0.001.
in our dataset was very limited and probably not sufficient
to fully describe the therapeutic preferences of the centre
personnel. We think that staff’s beliefs should be further in-
vestigated as possible determinant of treatment assignment.
It should also be considered that centres where a psychia-
trist is present might select higher risk patients, with poorer
psychosocial and medical health and severe substance disor-
ders, more likely to be assigned to maintenance. In fact, the
high value of the intra-class correlation coefficient supports
the hypothesis of heterogeneity among patients referring to
each treatment centre: some of the characteristics associated
to treatment assignment could also be interpreted as selec-
tion criteria for treatment entry, which work differently ac-
cording to organizational and structural characteristic of the
centre itself. In any case, the effect of a psychiatrist presence
on methadone maintenance remains even after adjusting for
severity.
We began our study by investigating determinants of
methadone assignment without distinguishing detoxification
and maintenance. This analysis did not allow for the identi-
fication of factors associated to the two different methadone
approaches but it helped to reveal the situations in which sub-
stitution therapy is assigned at first admissions. Preliminary
analysis of the VEdeTTE data (Amato et al., 2002a) showed
that methadone detoxification and methadone maintenance
treatments are often similar in practice. For example, the me-
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dian length of detoxification methadone treatment observed
in the VEdeTTE study is 31 days (range 1–517), versus 15
days as described in a Cochrane review (Amato et al., 2004);
whereas, the median length of methadone maintenance is 21
weeks with an average dosage of 40 mg (S.D. 19.8 mg), both
lower than recommended in the international scientific liter-
ature.
Therefore, most patients who were intended for detoxifi-
cation methadone actually received methadone maintenance
(stable doses of methadone over a prolonged period). On the
other hand, those intended-to-treat according to a methadone
maintenance approach received very low doses, for short pe-
riods.
A similar situation was found within the National Treat-
ment Outcome Research Study carried out in the United
Kingdom (Gossop et al., 2001). The authors observed that
many patients allocated to methadone reduction did not re-
ceive reduction treatment as intended, and called for a reap-
praisal of the goals and procedures of methadone reduction
treatment.
Some possible limitations of our study should be taken
into account when interpreting results. Firstly, in our study
data were derived from a subset of a larger sample of heroin
addicts enrolled in a longitudinal large scale study (Bargagli
et al., in press), which limits the generalizability of our find-
ings. The VEdeTTE cohort was compared to the total number
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the two groups are very similar according to demographic
and drug-use characteristics and they differ consistently by
long-term patients included in the VEdeTTE cohort. Con-
trolling for patients history of treatment did not change the
results.
In conclusion, we identified possible factors associated
with first treatment assignment among heroin addicts, and
found great heterogeneity between centres. Such heterogene-
ity cannot be explained by patients’ variables and should be
investigated further; it suggests the need for common admis-
sion guidelines for substitution treatment.
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